Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024096 · ClinicalTrials.gov registry record · Phase 4
Systems Biological Assessment of Statin Effect on Vaccine Responses
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
NCT06024096 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 63 participants.
The verdict
NCT06024096, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand how this medication affects long-lasting immune responses to vaccines. The researchers will study the immune response to the influenza vaccine in the blood (where antibodies are). The team will also look at how statin therapy affects the bacteria that live in the gut by collecting stool samples. To be in this research, participants must be adults willing to receive vaccines.
Interventions
- DRUG Atorvastatin
- BIOLOGICAL Quadrivalent seasonal influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2024-12-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06024096
The ClinicalTrials.gov registry entry for NCT06024096 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atorvastatin is the first listed.
NCT06024096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06024096 about?
NCT06024096 is a clinical study titled "Systems Biological Assessment of Statin Effect on Vaccine Responses". This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand how this medication affects long-lasting immune responses to vaccines. ...
What is the current status of trial NCT06024096?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2023-09-20. Estimated completion is 2024-12-16.
What interventions are being tested in trial NCT06024096?
The interventions under investigation include: Atorvastatin (DRUG), Quadrivalent seasonal influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06024096?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.